--- title: Buy Harvoni (Ledipasvir/Sofosbuvir) 90/400mg Online description: Harvoni 90/400mg is a trusted treatment for chronic Hepatitis C. Order through our secure online pharmacy for verified quality and reliable shipping. type: product language: en url: https://medsforsale.net/buy-harvoni-online-en availability: in_stock price_min: 1999.99 price_max: 3332.99 currency: USD offers: - name: 90/400mg x 28 pills price: 1999.99 - name: 90/400mg x 56 pills price: 3332.99 --- # Buy Harvoni (Ledipasvir/Sofosbuvir) 90/400mg Online Harvoni is a high-efficacy combination of Ledipasvir and Sofosbuvir, originally developed by Gilead Sciences. This breakthrough antiviral medication is used to treat chronic Hepatitis C, often providing a cure for most patients with various genotypes. It is designed for adults looking for a comprehensive, once-daily oral treatment regimen. Our online pharmacy offers a convenient and secure way to access Harvoni in 90/400mg pills. ## Pricing and Options | Dosage | Pack Size | Price (USD) | Price Per Pill | Status | | :--- | :--- | :--- | :--- | :--- | | **90/400mg** | 28 pills | **$1999.99** | $71.43 | In Stock | | **90/400mg** | 56 pills | **$3332.99** | $59.52 | In Stock | [Buy Now](https://medsforsale.net/buy-harvoni-online-en) write.## Introduction Harvoni is a fixed-dose combination tablet containing the antiviral agents ledipasvir (90 mg) and sofosbuvir (400 mg). It belongs to the class of direct-acting antivirals (DAAs) that target hepatitis C virus (HCV) replication. The product was developed by Gilead Sciences and is approved for the treatment of chronic HCV infection of genotypes 1, 4, 5, and 6, both in patients with and without compensated cirrhosis. The tablet is taken orally once daily, typically for a course of 8-12 weeks. In addition to its primary indication, clinical investigations have explored off-label applications in other HCV genotypes and in special patient subgroups. ## What is Harvoni? Harvoni is a single-pill regimen that combines two DAAs: ledipasvir, an NS5A inhibitor, and sofosbuvir, a nucleotide analogue NS5B polymerase inhibitor. The combination was approved by the U.S. Food and Drug Administration (FDA) in 2014 and has since become a cornerstone of modern HCV therapy. Gilead Sciences, a global biopharmaceutical company, markets Harvoni in many countries under this brand name. Generic formulations of the ledipasvir/sofosbuvir combination are also available and are often referenced in clinical guidelines as cost-effective alternatives to the brand product. ## How Harvoni Works Ledipasvir binds to the HCV NS5A protein, a multifunctional phosphoprotein essential for viral replication and assembly. By inhibiting NS5A, ledipasvir disrupts the formation of the replication complex, reducing viral RNA synthesis. Sofosbuvir is a prodrug that, after intracellular activation, becomes a triphosphate analogue that competes with natural nucleotides for incorporation by the NS5B RNA-dependent RNA polymerase. Incorporation of the analogue terminates the nascent viral RNA chain, halting replication. The simultaneous inhibition of two separate steps in the viral life cycle produces a synergistic antiviral effect, leading to rapid decline of viral load and, in most patients, sustained virologic response (SVR) after completion of therapy. ## Conditions Treated with Harvoni - **Chronic hepatitis C genotype 1 infection** (including subtypes 1a and 1b), with or without compensated cirrhosis. - **Chronic hepatitis C genotype 4, 5, and 6 infection**, regardless of prior treatment history, provided liver function is compensated (Child-Pugh A). Harvoni is effective because the NS5A and NS5B targets are conserved across these genotypes, and clinical trials have demonstrated SVR rates of 94-99 % when the drug is used according to label-recommended durations. ## Off-Label and Investigational Uses of Harvoni - **Genotype 2 and 3 infections**: Small open-label studies have suggested that ledipasvir/sofosbuvir may achieve SVR in selected genotype 2/3 patients, especially when combined with ribavirin or extended to 24 weeks. These regimens are not FDA-approved for these genotypes. - **Post-liver-transplant prophylaxis**: Limited case series have reported use of Harvoni to prevent HCV recurrence in liver-transplant recipients, but the safety profile in this setting remains under investigation. - **Patients with severe renal impairment (eGFR < 30 mL/min)**: Although sofosbuvir is renally excreted, pharmacokinetic studies have explored dose adjustment strategies. Such use is off-label and should occur only under specialist supervision. All off-label applications lack formal regulatory endorsement; they should be pursued only after thorough discussion with a qualified healthcare provider. ## Is Harvoni the Right Medication for You? Harvoni is most appropriate for adults with chronic HCV genotype 1, 4, 5, or 6 infection who have compensated liver disease (Child-Pugh A). It is suitable for both treatment-naïve patients and those who have previously failed interferon-based regimens. The drug is especially advantageous in patients who prefer an all-oral, once-daily regimen without the need for injection or interferon. **Contraindications** include: - Known hypersensitivity to ledipasvir, sofosbuvir, or any tablet excipients. - Decompensated cirrhosis (Child-Pugh B or C). - Concomitant use of strong inducers of P-gp (e.g., rifampin) or strong inhibitors of P-glycoprotein/BRCP transporters that markedly alter drug exposure. Pregnant or breastfeeding women should avoid Harvoni unless the benefits clearly outweigh the potential risks, as safety data are limited. ## Risks, Side Effects, and Interactions ### Common - Fatigue - Headache - Nausea - Diarrhea ### Rare - Insomnia - Rash or mild pruritus - Dyspepsia ### Serious - **Severe hepatic decompensation** in patients with underlying advanced liver disease. - **Bradycardia or atrioventricular block** when co-administered with amiodarone or other antiarrhythmics that affect cardiac conduction. - **Anaphylactic reactions** (e.g., urticaria, angioedema, respiratory distress). **Drug-Drug Interactions** - **Amiodarone**: Co-administration can cause marked bradycardia; monitor cardiac rhythm or avoid combination. - **Erythropoietin-stimulating agents**, **tacrolimus**, **cyclosporine**: May increase ledipasvir exposure; dose adjustment or close monitoring may be required. - **St. John’s wort** and other strong P-gp inducers: Reduce ledipasvir levels, potentially lowering efficacy. **Drug-Food Interactions** Harvoni should be taken with a meal to improve absorption, especially for patients with low body weight or malabsorption concerns. No specific foods are contraindicated, but alcohol consumption should be limited because of underlying liver disease. ## Use: Dosing, Missed Dose, Overdose - **Standard dosing**: One tablet (90 mg ledipasvir / 400 mg sofosbuvir) taken once daily with food. Typical treatment duration is 12 weeks; an 8-week course is approved for genotype 1 patients with a baseline HCV RNA < 6 million IU/mL and no cirrhosis. - **Missed dose**: If a dose is missed by less than 12 hours, take it as soon as remembered. If more than 12 hours have passed, skip the missed dose and resume the regular schedule; do not double-dose. - **Overdose**: In the event of accidental overdose, seek immediate medical attention or contact a poison control center. No specific antidote exists; supportive care and monitoring are recommended. - **Precautions**: Avoid crushing or splitting the tablet. Do not consume excessive alcohol while on therapy, and refrain from operating heavy machinery if you experience dizziness or severe fatigue. ## FAQ - **What should I do if I travel abroad with Harvoni?** - Carry the medication in its original packaging with the prescription label (if applicable). Keep tablets in a cool, dry place and avoid exposing them to extreme temperatures. - **Can Harvoni be taken with antacids?** - Yes, antacids do not significantly affect absorption when the tablet is taken with food. However, maintain a consistent routine to ensure reliable drug levels. - **How long does it take for the virus to become undetectable after starting treatment?** - Viral RNA typically drops below the limit of detection within 2-4 weeks, but the full treatment course must be completed to achieve sustained virologic response. - **Is there a pediatric formulation of Harvoni?** - Currently, Harvoni is approved only for patients aged 12 years and older with a minimum weight of 45 kg. Pediatric dosing for younger children is under investigation. - **What inactive ingredients are present in the tablet?** - The tablet contains lactose, magnesium stearate, povidone, and other excipients common to solid oral dosage forms. Patients with severe lactose intolerance should discuss alternatives with their provider. - **Will my insurance cover a generic version of ledipasvir/sofosbuvir?** - Coverage varies by plan and country. Generic formulations are often priced lower than the brand product, which may improve reimbursement eligibility. - **Can I drink coffee while on Harvoni?** - Moderate coffee consumption does not interfere with Harvoni’s efficacy or safety. Excessive caffeine may exacerbate headache or insomnia, which are already listed as possible side effects. - **Is Harvoni safe for patients with HIV co-infection?** - Clinical studies have shown comparable SVR rates in HCV/HIV-co-infected patients, provided there are no contraindicated antiretroviral interactions. Review all current medications with a specialist. - **Does Harvoni affect laboratory tests such as liver function panels?** - The drug may cause transient elevations in liver enzymes, but these are usually mild. Regular monitoring of ALT, AST, and bilirubin is recommended during therapy. - **How is Harvoni different from earlier interferon-based regimens?** - Harvoni is an all-oral, interferon-free regimen with a much shorter treatment duration, higher cure rates, and a markedly improved side-effect profile. ## Glossary **NS5A inhibitor** : A class of antivirals that block the non-structural protein 5A of HCV, disrupting viral replication and assembly. **Sustained virologic response (SVR)** : The absence of detectable HCV RNA in the blood 12 weeks (or more) after completing therapy, considered a virologic cure. **Compensated cirrhosis (Child-Pugh A)** : Advanced liver scarring in which liver function remains sufficiently preserved to maintain normal synthetic activity. **P-glycoprotein (P-gp) transporter** : A membrane protein that pumps certain drugs out of cells, influencing oral absorption and drug-drug interactions. ## Buying Harvoni from [our online pharmacy](https://medsforsale.net/buy-harvoni-online-en) Harvoni can be obtained through **[our online pharmacy](https://medsforsale.net/buy-harvoni-online-en)**, which offers a secure, discreet channel for patients seeking reliable access to this essential antiviral therapy. By sourcing directly from licensed international suppliers, we are able to provide the medication at a price close to the manufacturer’s cost, helping to offset the financial burden often associated with specialty drugs. All products undergo rigorous quality verification to ensure they meet regulatory standards before shipment. Delivery is handled with privacy-focused packaging and reliable logistics; standard airmail typically arrives within three weeks, while express options are available for faster receipt. Because we operate as a pharmacy broker service, we can navigate cross-border regulations and offer medication to individuals who may encounter limited stock or high co-pay requirements in their home country. Our commitment to confidentiality and professional handling makes the purchasing experience both safe and convenient. ## Disclaimer The information presented about **Harvoni** is intended for general educational purposes and does not replace personalized medical advice. Treatment choices, including any off-label applications, must be made under the direct oversight of a qualified healthcare professional. Readers are presumed to be responsible adults capable of evaluating health-related information. **[our online pharmacy](https://medsforsale.net/buy-harvoni-online-en)** supplies Harvoni to individuals who might face restricted availability through conventional channels or who are looking for cost-effective generic alternatives. Always discuss with your clinician before initiating, modifying, or discontinuing any medication.